Versant Capital Management, Inc Dyne Therapeutics, Inc. Transaction History
Versant Capital Management, Inc
- $710 Million
- Q3 2025
A detailed history of Versant Capital Management, Inc transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 859 shares of DYN stock, worth $19,473. This represents 0.0% of its overall portfolio holdings.
Number of Shares
859
Previous 44
1852.27%
Holding current value
$19,473
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
122MCall Options Held
36.5KPut Options Held
74.3K-
Ra Capital Management, L.P. Boston, MA9.71MShares$220 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$214 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$207 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$173 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$167 Million0.01% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.17B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...